NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia.

@article{Kimura2005NS187AP,
  title={NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia.},
  author={S. Kimura and H. Naito and H. Segawa and J. Kuroda and T. Yuasa and Kiyoshi Sato and A. Yokota and Y. Kamitsuji and E. Kawata and E. Ashihara and Y. Nakaya and H. Naruoka and T. Wakayama and K. Nasu and T. Asaki and T. Niwa and K. Hirabayashi and T. Maekawa},
  journal={Blood},
  year={2005},
  volume={106 12},
  pages={
          3948-54
        }
}
Although the Abelson (Abl) tyrosine kinase inhibitor imatinib mesylate has improved the treatment of breakpoint cluster region-Abl (Bcr-Abl)-positive leukemia, resistance is often reported in patients with advanced-stage disease. Although several Src inhibitors are more effective than imatinib and simultaneously inhibit Lyn, whose overexpression is associated with imatinib resistance, these inhibitors are less specific than imatinib. We have identified a specific dual Abl-Lyn inhibitor, NS-187… Expand

Paper Mentions

Blog Post
Development of NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor
Bcr-Abl Kinase Inhibitors
The Second Generation of BCR-ABL Tyrosine Kinase Inhibitors
Bcr-Abl tyrosine kinase inhibitors- current status
The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias
NS-187 (INNO-406), a Bcr-Abl/Lyn Dual Tyrosine Kinase Inhibitor
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 47 REFERENCES
A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.
  • K. Gumireddy, S. Baker, +5 authors E. Reddy
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 2005
Mechanisms and implications of imatinib resistance mutations in BCR-ABL
...
1
2
3
4
5
...